샘플 요청 목록

 카트 문의
시장보고서
상품코드
1781300

세계의 특발성 혈소판 감소성 자반증 치료제 시장

Idiopathic Thrombocytopenic Purpura Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 277 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

특발성 혈소판 감소성 자반증 치료제 세계 시장, 2030년까지 8억 4,750만 달러에 달할 전망

2024년 6억 6,590만 달러로 추정되는 특발성 혈소판 감소성 자반증 치료제 세계 시장은 2030년에는 8억 4,750만 달러에 달할 것으로 예상되며, 분석 기간인 2024-2030년 동안 4.1%의 CAGR로 성장할 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 급성 면역성 혈소판 감소성 자반병은 CAGR 4.6%를 기록하며 분석 기간 종료 시점에 5억 2,540만 달러에 달할 것으로 예상됩니다. 만성질환 부문의 성장률은 분석 기간 동안 CAGR 3.5%로 추정됩니다.

미국 시장 1억 8,140만 달러로 추정, 중국은 CAGR 7.6%로 성장 전망

미국의 특발성 혈소판 감소성 자반증 치료제 시장은 2024년 1억 8,140만 달러에 달할 것으로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 1억 7,360만 달러의 시장 규모에 도달할 것으로 예상되며, 분석 기간인 2024-2030년의 CAGR은 7.6%에 달할 것으로 예상됩니다. 주목할 만한 다른 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 1.6%와 3.2%의 CAGR을 기록할 것으로 예상됩니다. 유럽에서는 독일이 CAGR 2.4%로 성장할 것으로 예상됩니다.

특발성 혈소판 감소성 자반병(ITP) 치료제의 최신 치료 전략은?

특발성 혈소판 감소성 자반증(ITP) 치료제 세계 시장 - 주요 동향 및 촉진요인 정리

특발성 혈소판 감소성 자반병(ITP) 치료제 세계 시장은 질환의 유병률 증가와 치료법의 발전에 힘입어 꾸준히 성장하고 있습니다. ITP는 혈소판 수 감소를 특징으로 하는 자가면역질환으로 출혈과 타박상을 유발하는 질환입니다. 이 시장에는 부신피질 스테로이드, 정맥주사 면역글로불린(IVIG), 항D 면역글로불린, 트롬보포이에틴 수용체 작용제(TPO-RA), 환자의 예후를 개선하기 위한 새로운 치료법 등 다양한 치료 옵션이 있습니다.

ITP의 치료 전략은 진화하고 있으며, 가이드라인에서는 출혈 위험도, 혈소판 수, 기존 치료에 대한 반응성을 바탕으로 환자 개개인에 맞는 치료를 강조하고 있습니다.

어떤 혁신이 ITP 치료의 전망을 바꾸고 있는가?

ITP 치료제의 상황은 효과와 환자의 삶의 질을 향상시키는 것을 목표로 하는 중요한 기술 혁신에 직면해 있습니다. 새로운 치료법은 비장 티로신 키나아제(SYK) 억제제, 신생아 Fc 수용체(FcRn) 길항제 등 혈소판 파괴에 관여하는 면역 경로를 조절하는 새로운 작용 기전에 초점을 맞추고 있습니다. 이러한 발전은 난치성 ITP 환자나 기존 치료제에 내약성이 없는 환자들에게 새로운 치료 대안이 될 수 있습니다.

또한, 바이오마커를 이용하여 치료 반응을 예측하고 그에 따라 치료를 조정하는 맞춤형 의료 접근법도 검토되고 있습니다. 이 개별화 전략은 치료 결과를 최적화하고 부작용을 최소화하는 것을 목표로 합니다. 또한, 바이오시밀러 및 기존 의약품의 개량형 제제 개발로 치료 접근성 및 환자 순응도가 향상되고 있습니다.

ITP 치료제 시장의 성장은 몇 가지 요인에 의해 발생합니다.

ITP 치료제 시장의 확대는 다음과 같은 몇 가지 중요한 요인에 의해 촉진되고 있습니다.

  • 치료 옵션의 발전 : 새로운 치료제와 표적 치료제의 도입으로 치료 옵션의 폭이 넓어지고, 다양한 중증도와 치료 이력을 가진 환자들에게 대응할 수 있게 되었습니다.
  • 질병에 대한 인식과 진단 향상 : 의료진과 환자의 인식 향상은 조기 진단과 조기 개입으로 이어져 환자 결과를 개선하고 치료 대상자를 확대했습니다.
  • 고령화 : 전 세계 인구의 고령화에 따라 노년층의 ITP 유병률이 높아짐에 따라 ITP 발병률은 증가할 것으로 예상되며, 효과적인 치료제에 대한 수요가 증가하고 있습니다.
  • 전략적 제휴 및 연구 이니셔티브 : 제약사, 연구기관, 환자 지원 단체의 협력은 혁신적인 치료법 개발 및 임상시험을 촉진하고 새로운 치료법의 시장 개발을 가속화하고 있습니다.

이러한 요인들로 인해 ITP 치료제 시장은 미충족 의료 수요에 대한 대응과 ITP 환자의 삶의 질 향상을 목표로 역동적인 성장과 진화를 거듭하고 있습니다.

부문

질환(급성 면역성 혈소판 감소성 자반증, 만성질환, 기타 질환), 제품(부신피질 스테로이드, IVIG, 항D면역글로불린, TPO-RA, 기타)

조사 대상 기업 예시

  • Amgen Inc.
  • argenx SE
  • eXIthera Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Grifols, S.A.
  • GSK plc.
  • Harbour BioMed
  • HUTCHMED
  • InnoCare Pharma Limited
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Keros Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Principia Biopharma (acquired by Sanofi)
  • Qilu Pharmaceutical Co., Ltd.
  • Rigel Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • UCB S.A.
  • Veralox Therapeutics, Inc.

AI 통합

Global Industry Analysts는 효과적인 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신합니다.

Global Industry Analysts는 일반적인 LLM이나 산업별 SLM에 쿼리하는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 전 세계 전문가들로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.12

Global Idiopathic Thrombocytopenic Purpura Therapeutics Market to Reach US$847.5 Million by 2030

The global market for Idiopathic Thrombocytopenic Purpura Therapeutics estimated at US$665.9 Million in the year 2024, is expected to reach US$847.5 Million by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Acute Immune Thrombocytopenic Purpura Disease, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$525.4 Million by the end of the analysis period. Growth in the Chronic Disease segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$181.4 Million While China is Forecast to Grow at 7.6% CAGR

The Idiopathic Thrombocytopenic Purpura Therapeutics market in the U.S. is estimated at US$181.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$173.6 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics: What Are the Latest Advances in Treatment Strategies?

Global ITP Therapeutics Market - Key Trends & Drivers Summarized

The global market for Idiopathic Thrombocytopenic Purpura (ITP) therapeutics is experiencing steady growth, driven by an increasing prevalence of the disorder and advancements in treatment modalities. ITP is an autoimmune condition characterized by a low platelet count, leading to bleeding and bruising. The market encompasses various therapeutic options, including corticosteroids, intravenous immunoglobulins (IVIG), anti-D immunoglobulins, thrombopoietin receptor agonists (TPO-RAs), and emerging treatments aimed at improving patient outcomes.

Treatment strategies for ITP have evolved, with guidelines emphasizing individualized patient care based on bleeding risk, platelet count, and response to previous therapies.

Which Innovations Are Transforming the ITP Therapeutics Landscape?

The ITP therapeutics landscape is witnessing significant innovations aimed at enhancing efficacy and patient quality of life. Emerging therapies are focusing on novel mechanisms of action, such as spleen tyrosine kinase (SYK) inhibitors and neonatal Fc receptor (FcRn) antagonists, which modulate immune pathways involved in platelet destruction. These advancements offer potential alternatives for patients with refractory ITP or those intolerant to existing treatments.?

Additionally, personalized medicine approaches are being explored, utilizing biomarkers to predict treatment responses and tailor therapies accordingly. This individualized strategy aims to optimize outcomes and minimize adverse effects. Furthermore, the development of biosimilars and improved formulations of existing drugs is enhancing accessibility and patient adherence to treatment regimens.?

The Growth in the ITP Therapeutics Market Is Driven by Several Factors…

The expansion of the ITP therapeutics market is propelled by several key factors:?

  • Advancements in Treatment Options: The introduction of novel therapies and targeted agents has broadened the spectrum of treatment choices, catering to patients with varying disease severities and treatment histories.?
  • Increased Disease Awareness and Diagnosis: Enhanced awareness among healthcare professionals and patients has led to earlier diagnosis and intervention, improving patient outcomes and expanding the treatment-eligible population.?
  • Aging Population: As the global population ages, the incidence of ITP is expected to rise, given its higher prevalence among older individuals, thereby driving demand for effective therapeutics.
  • Strategic Collaborations and Research Initiatives: Collaborations between pharmaceutical companies, research institutions, and patient advocacy groups are fostering the development of innovative treatments and facilitating clinical trials, accelerating the introduction of new therapies to the market.?

Collectively, these factors are contributing to the dynamic growth and evolution of the ITP therapeutics market, aiming to address unmet medical needs and enhance the quality of life for patients with ITP.?

SCOPE OF STUDY:

The report analyzes the Idiopathic Thrombocytopenic Purpura Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease (Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease, Other Diseases); Product (Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics, Other Idiopathic Thrombocytopenic Purpura Therapeutic Products)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Amgen Inc.
  • argenx SE
  • eXIthera Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Grifols, S.A.
  • GSK plc.
  • Harbour BioMed
  • HUTCHMED
  • InnoCare Pharma Limited
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Keros Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Principia Biopharma (acquired by Sanofi)
  • Qilu Pharmaceutical Co., Ltd.
  • Rigel Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • UCB S.A.
  • Veralox Therapeutics, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Idiopathic Thrombocytopenic Purpura Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Disease Awareness and Early Diagnosis Propel Demand for ITP Therapies
    • Increased Use of Thrombopoietin Receptor Agonists Drives Growth in Second-Line Treatments
    • Development of Novel Targeted Biologics Expands Therapeutic Options for Chronic ITP
    • Growing Pediatric and Geriatric Patient Pools Create Demand for Tailored Treatment Regimens
    • Advances in Autoimmune Disease Understanding Strengthen Business Case for Precision Therapies
    • Increasing Clinical Trial Activity Spurs Innovation in Next-Gen ITP Therapeutics
    • Growing Use of Combination Therapies Enhances Treatment Outcomes and Market Differentiation
    • Regulatory Fast Track and Orphan Drug Designations Accelerate Product Launch Timelines
    • Physician Education and Updated Treatment Guidelines Drive Adoption of New Drug Classes
    • Improved Diagnostic Accuracy and Biomarker Research Throws Spotlight on Personalized ITP Treatment
    • Expansion of Hospital-Based Infusion Services Facilitates Uptake of Intravenous Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Idiopathic Thrombocytopenic Purpura Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Acute Immune Thrombocytopenic Purpura Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Acute Immune Thrombocytopenic Purpura Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Acute Immune Thrombocytopenic Purpura Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chronic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Chronic Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for IVIG Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for IVIG Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for IVIG Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Idiopathic Thrombocytopenic Purpura Therapeutic Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Idiopathic Thrombocytopenic Purpura Therapeutic Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Idiopathic Thrombocytopenic Purpura Therapeutic Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • JAPAN
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • CHINA
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • EUROPE
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • FRANCE
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • GERMANY
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • INDIA
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030
  • AFRICA
    • Idiopathic Thrombocytopenic Purpura Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Disease - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenic Purpura Disease, Chronic Disease and Other Diseases for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Idiopathic Thrombocytopenic Purpura Therapeutics by Product - Percentage Breakdown of Value Sales for Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics, IVIG Idiopathic Thrombocytopenic Purpura Therapeutics, Anti-D Immunoglobulins Idiopathic Thrombocytopenic Purpura Therapeutics, TPO-RA Idiopathic Thrombocytopenic Purpura Therapeutics and Other Idiopathic Thrombocytopenic Purpura Therapeutic Products for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제